Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 8:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 190 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-Hodgkin Lymphoma
Interventions
Carboplatin, Etoposide, Filgrastim, Ifosfamide, Leukapheresis, Plerixafor, Rituximab
Drug · Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Metabolic Syndrome
Interventions
Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
Behavioral
Lead sponsor
Family Medicine Residency of Idaho
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Caldwell, Idaho • Jerome, Idaho • Nampa, Idaho
Completed Not applicable Interventional Accepts healthy volunteers

OB Nest; Redefining Continuity of Care for Expectant Mothers

NCT02082275
Conditions
Pregnancy
Interventions
OB Nest
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pancreatic Cancer
Interventions
Biopsy, FOLFIRINOX, Ciprofloxacin, Metronidazole, Pembrolizumab, Surgical Resection
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Terminated Phase 2 Interventional Accepts healthy volunteers

Sargramostim for Myeloid Dendritic Cell Deficiency

NCT03063242
Conditions
Kidney Diseases, Kidney Transplant
Interventions
Sargramostim, Blood samples
Drug · Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
Interventions
Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Spinal Cord Injuries
Interventions
Acute Intermitted Hypoxia, Massed Practise, Rapael Glove
Other · Procedure
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • East Hanover, New Jersey
Conditions
SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
Interventions
Physical examination, Electrocardiogram, SF-36 questionnaire, Clinical laboratory evaluations - Serology, Clinical laboratory evaluations - Biochemistry, Clinical laboratory evaluations - Hematology, Pregnancy Test, Urinalysis, SLE activity evaluation, SLE biomarker profiling, Cytokines and chemokine profiling, single dose of UC-MSCs, PROMIS instruments
Diagnostic Test · Other · Biological
Lead sponsor
LiveKidney.Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Breast Cancer
Interventions
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
Behavioral · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I AIDS-related Lymphoma, Stage II AIDS-related Lymphoma, Stage III AIDS-related Lymphoma, Stage IV AIDS-related Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
carmustine, cytarabine, melphalan, etoposide, O6-benzylguanine, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

ImmunoBoost: The Lymphatic Osteopathic Manipulative Treatment Protocol Study

NCT06565065
Conditions
Healthy
Interventions
Osteopathic Manipulative Treatment (OMT), Sham Light Touch, Exercise Protocol
Procedure · Other
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pomona, California
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diffuse Large B-cell-lymphoma
Interventions
Venetoclax, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
St Louis, Missouri • Cleveland, Ohio
Completed Not applicable Interventional Results available

Blood Flow Restriction Training (BFR) in an Adolescent Population

NCT04285879
Conditions
Blood Flow Restriction, ACL Tear, ACL Injury
Interventions
Blood Flow Restriction using Delfi Personalized Tourniquet System
Device
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
12 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Sickle Cell Anemia
Interventions
Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
24 Months to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 9 more
Conditions
Neuroblastoma
Interventions
Carboplatin, Autologous stem cell infusion, Granulocyte colony stimulating factor, Radiation therapy, Isotretinoin (13-cis-retinoic acid), Melphalan, Etoposide
Drug · Biological · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Analytical and Clinical Performance Testing Plan

NCT03595501
Conditions
Hematology, Hematologic Test
Interventions
Hematology Analyzer - OLO, Hematology Analyzer - Predicate
Device
Lead sponsor
Sight Diagnostics
Industry
Eligibility
3 Months and older
Enrollment
679 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer
Interventions
Hydroxychloroquine (HCQ), Gedatolisib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Advanced Soft-tissue Sarcoma
Interventions
Lurbinectedin
Drug
Lead sponsor
ERLINDA M GORDON
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Coronary Artery Disease
Interventions
Questionnaire of overall health
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Neuroblastoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, isotretinoin, melphalan, topotecan hydrochloride, vincristine sulfate, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 76 more